Medicare AdvantageAdministrativeHigh impact
MA08.011i, Erythropoiesis Stimulating Agents (ESAs)
Independence Blue Cross·Hematology, Oncology, Nephrology +1 more·Medical Policy
Effective date
Jun 15, 2026
We identified it
Jun 19, 2026
Summary
Policy MA08.011i updates medical necessity criteria and medical coding requirements for Erythropoiesis Stimulating Agents (ESAs). This recent policy change affects how ESA claims are evaluated and coded for Medicare Advantage members, requiring billing and clinical teams to implement new documentation and coding standards effective immediately.
Action Required
By 06/15/2026: Billing team and clinical staff must obtain and review the complete MA08.011i ESA policy from the source URL. 1) Update billing system coding rules to reflect new medical coding requirements for ESA claims. 2) Implement new medical necessity criteria in prior authorization workflows—ensure all ESA claims validate against updated criteria before submission. 3) Train providers and clinical staff on revised documentation requirements for ESA medical necessity. 4) Audit EMR templates to ensure ESA-related encounter notes capture required documentation elements. 5) Create internal policy reference guide for billing staff. Failure to align with new criteria will result in claim denials and rework. NOTE: The specific affected CPT/HCPCS codes and detailed criteria are not visible in the policy header—access the full policy document at the provided URL to extract specific code changes and implementation requirements.